[go: up one dir, main page]

AU2010224720A1 - Derivatives of N-[(2-aza-bicyclo [2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics - Google Patents

Derivatives of N-[(2-aza-bicyclo [2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics Download PDF

Info

Publication number
AU2010224720A1
AU2010224720A1 AU2010224720A AU2010224720A AU2010224720A1 AU 2010224720 A1 AU2010224720 A1 AU 2010224720A1 AU 2010224720 A AU2010224720 A AU 2010224720A AU 2010224720 A AU2010224720 A AU 2010224720A AU 2010224720 A1 AU2010224720 A1 AU 2010224720A1
Authority
AU
Australia
Prior art keywords
hex
azabicyclo
compound
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010224720A
Inventor
Genevieve Estenne-Bouhtou
Abdel-Kader Mafroud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0901219A external-priority patent/FR2943056A1/en
Priority claimed from FR0901810A external-priority patent/FR2944283B1/en
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2010224720A1 publication Critical patent/AU2010224720A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to compounds of general formula (I) wherein R is a hydrogen atom or a group selected from the groups (C-C) aIkyI, (C-C) cycloalkyl, benzyl or allyl optionally substituted by at least one group selected independently from each other from the halogen atoms, the groups (C-C) cycloalkyl, (C-C) alkyl, (C-C) BlCOXy, hydroxy; R is a phenyl or naphtyl group, optionally substituted by at least one substitutent selected independently from each other from the halogen atoms, the groups (CrC6) alkyl, (C-C) BlCOXy, halo-(C-C) alkyl, hydroxy, halo-(CC) alcoxy, (C-C) alkyl-thio, (C-C)alkyl-SO, (CC) alkyl-SO; Het is a heteroaryl group; and R is at least one substituent selected from the hydrogen atom, the halogen atoms, the groups halo-(d-C) alkyl, (CC) alkyl, (C-C) cycloalkyl, (C-C)-cycloalkyl-(C-C) alkyl, (C- C) alcoxy, benzyl, (CC) alkyl-thio, (CC) alkyl-SO, (CC) alkyl-SO; in the base state or as addition salts for acids. The invention also relates to the use of said compounds in therapeutics and synthesis methods.

Description

WO 2010/106269 1 PCT/FR2010/050447 DERIVATIVES OF N-[(2-AZA-B I CYCLO[2.1.11 HEX-1 -YL)-ARYL-)M ETHYL] HETEROBENZAMIDE, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS 5 The present invention relates to N-[(2-azabicyclo[2.2.1 ]hex- 1 -yl)(aryl)methyl] heterobenzamide derivatives, to their preparation and to their therapeutic application in the treatment or prevention of diseases involving glycine transporters GIyT1. 10 The compounds of the invention correspond to the general formula (1) R, N I N 0 ) R H Het R 2 in which: - R represents a hydrogen atom or a group chosen from (CI-C 6 )alkyl, (C3-C 7 )cycio alkyl, benzyl or allyl groups which is optionally substituted by one or more groups 15 chosen, independently of one another, from halogen atoms or (C 3
-C
7 )cycloalkyl,
(C-C
8 )alkyl, (C 1
-C
6 )alkoxy or hydroxyl groups; - R 1 represents a phenyl or naphthyl group which is optionally substituted by one or more substituents chosen, independently of one another, from halogen atoms or (CI-Cs)alkyl, (C-C 6 )alkoxy, halo(C-C 6 )alkyl, hydroxyl, halo(C-C 6 )alkoxy, (C 20 C 6 )alkylthio, (CI-C 6 )alkyl-SO or (C-C 6 )alkyl-SO 2 groups; - Het represents a heteroaryl group; - R 2 represents one or more substituents chosen from the hydrogen atom, halogen atoms or halo(Cr7C 6 )alkyl, (CrC 6 )alkyl, (C 3 -C)cycloalkyl, (C 3 -C7)cycloalkyl(C 1
-C
3 )alkyl,
(C-C
6 )alkoxy, benzyl, (C-Ce)alkylthio, (C-C 6 )alkyl-SO or (C-C 6 )alkyl-SO 2 groups; 25 in the form of the base or of an addition salt with an acid. The compounds of formula (1) comprise an asymmetric carbon atom. They can thus exist in the form of enantiomers. These enantiomers, including racemic mixtures, come within the scope of the invention.
WO 2010/106269 2 PCT/FR2010/050447 The compounds of formula (I) can exist in the form of bases or of addition salts with acids. Such addition salts come within the scope of the invention. 5 These salts are advantageously prepared with pharmaceutically acceptable acids but the salts of other acids, for example for use in the purification or isolation of the compounds of formula (1), also come within the invention. In the context of the invention: 10 - CrCt, where t and z can take the values from 1 to 6, is understood to mean a carbon chain which can have from t to z carbon atoms; for example, C-Ce is understood to mean a carbon chain which can have from 1 to 6 carbon atoms; - alkyl is understood to mean a saturated, linear or branched, aliphatic group; for example, a (CI-C 6 )alkyl group represents a linear or branched carbon chain of 1 to 15 6 carbon atoms, for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert butyl, pentyl or hexyl; - alkoxy is understood to mean an -0-alkyl group; - hydroxyl is understood to mean an -OH group; - ally] is understood to mean a -(CH 2
)-CH=CH
2 group; 20 - alkylthio is understood to mean a sulphur atom substituted by an alkyl group; - halogen atom is understood to mean a fluorine, a chlorine, a bromine or an iodine; - haloalkyl is understood to mean an alkyl group, one or more hydrogen atoms of which have been replaced by a halogen. Mention may be made, by way of examples, of the trifluoromethyl, trifluoroethyl or pentafluoroethyl groups; 25 - heteroaryl group is understood to mean a 5- or 10-membered hetero-aromatic mono- or bicyclic group comprising from 1 to 3 heteroatoms chosen from nitrogen, oxygen and sulphur. Mention may be made, as examples of heteroaryl group, of the pyrrole, furan, thiophene, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, thiadiazole, pyridine, pyrimidine, 30 pyrazine, pyridazine, triazine, indole, isoindole, benzimidazole, indazole, indolizine, benzofuran, isobenzofuran, benzothiophene, benzo[c]thiophene, pyrrolopyridine, imidazopyridine, pyrazolopyridine, triazolopyridine, tetrazolopyridine, pyrrolopyrimidine, imidazopyrimidine, pyrazolopyrimidine, triazolopyrimidine, tetrazolopyrimidine, pyrrolopyrazine, imidazopyrazine, pyrazolopyrazine, 35 triazolopyrazine, tetrazolopyrazine, pyrrolopyridazine, imidazopyridazine, WO 2010/106269 3 PCT/FR2010/050447 pyrazolopyridazine, triazolopyridazine, tetrazolopyridazine, pyrrolotriazine, imidazotriazine, pyrazolotriazine, triazolotriazine, tetrazolotriazine, furopyridine, furopyrimidine, furopyrazine, furopyridazine, furotriazine, oxazolopyridine, oxazolopyrimidine, oxazolopyrazine, oxazolopyridazine, oxazolotriazine, 5 isoxazolopyridine, isoxazolopyrimidine, isoxazolopyrazine, isoxazolopyridazine, isoxazolatriazine, oxadiazolopyridine, oxadiazolopyrimidine, oxadiazolopyrazine, oxadiazolopyridazine, oxadiazolotriazine, benzoxazole, benzisoxazole, benzoxadiazole, thienopyridine, thienopyrimidine, thienopyrazine, thienopyridazine, thienotriazine, thiazolopyridine, thiazolopyrimidine, thiazolopyrazine, 10 thiazolopyridazine, thiazolotriazine, isothiazolopyridine, isothiazolopyrimidine, isothiazolopyrazine, isothiazolopyridazine, isothiazolotriazine, thiadiazolopyridine, thiadiazolopyrimidine, thiadiazolopyrazine, thiadiazolopyridazine, thiadiazolotriazine, benzothiazole, benzisothiazole, benzothiadiazole, quinoline, isoquinoline, cinnoline, phthalazine, quinoxaline, quinazoline, naphthyridine, 15 benzotriazine, pyridopyrimidine, pyridopyrazine, pyridopyridazine, pyridotriazine, pyrimidopyrimidine, pyrimidopyrazine, pyrimidopyridazine, pyrimidotriazine, pyrazinopyrazine, pyrazinopyridazine, pyrazinotriazine, pyridazinopyridazine or pyridazinotriazine groups. 20 Among the compounds of general formula (I) which are subject-matters of the invention, a first group of compounds is composed of the compounds for which: - R represents a hydrogen atom, a benzyl group or an allyl group; - R 1 , Het and R 2 being as defined above, in the form of the base or of an addition salt with an acid. 25 Among the compounds of general formula (1) which are subject-matters of the invention, a second group of compounds is composed of the compounds for which: - R 1 represents a phenyl or a naphthyl group which is optionally substituted by one or more groups chosen, independently of one another, from halogen atoms or (Cr 30 C 6 )alkyl, (C-C 6 )alcoxy or halo(C-Ce)alkyl groups; - R, Het and R 2 being as defined above, in the form of the base or of an addition salt with an acid. Among the compounds of general formula (I) which are subject-matters of the 35 invention, a third group of compounds is composed of the compounds for which: WO 2010/106269 4 PCT/FR2010/050447 - Het represents an indole, thiophene or pyridine group; - R, R, and R 2 being as defined above, in the form of the base or of an addition salt with an acid. 5 Among the compounds of general formula (I) which are subject-matters of the invention, a fourth group of compounds is composed of the compounds for which: - R 2 represents one or more substituents chosen from the hydrogen atom, halogen atoms or halo(C-C 6 )alkyl, benzyl or (CI-C 6 )alkylthio groups; - R, R 1 and Het being as defined above, 10 in the form of the base or of an addition salt with an acid. Among the compounds of general formula (1) which are subject-matters of the invention, a fifth group of compounds is composed of the compounds for which: - R represents a hydrogen atom, a benzyl group or an allyl group; 15 - R 1 represents a phenyl or naphthyl group which is optionally substituted by one or more substituents chosen, independently of one another, from halogen atoms or
(C-C
6 )alkyl, (C-C 6 )alcoxy or halo(Cr-C 6 )alkyl groups; - Het represents an indole, thiophene or pyridine group; - R 2 represents one or more substituents chosen from the hydrogen atom, halogen 20 atoms or halo(C-C 6 )alkyl, benzyl or (Cl-Ce)alkylthio groups; in the form of the base or of an addition salt with an acid. Among the compounds of general formula (1) which are subject-matters of the invention, a sixth group of compounds is composed of the compounds for which: 25 - R represents a hydrogen atom, a benzyl group or an allyl group; - R, represents a phenyl or naphthyl group which is optionally substituted by one or more substituents chosen, independently of one another, from the fluorine atom or methyl, methoxy or trifluoromethyl groups; - Het represents an indole, thiophene or pyridine group; 30 - R 2 represents one or more substituents chosen from the hydrogen atom, bromine or chlorine atoms or trifluoromethyl, methylthio or benzyl groups; in the form of the base or of an addition salt with an acid. The combinations of the groups one to six above also come within the scope of the 35 invention.
WO 2010/106269 5 PCT/FR2010/050447 Mention may in particular be made, among the compounds of general formula (1) which are subject-matters of the invention, of the following compounds: 5 N-[(2-Allyl-2-azabicyclo[2.1.1]hex-1 -yl)(phenyl)methyl-4,5-dibromothiophene-2 carboxamide; N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yl)(phenyl)methyl]-4,5-di bromothiophene-2-carboxamide; N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yl)(phenyl)methylj-2,5-dichlorothiophene-3-carboxam ide; (+)-N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yl)(phenyl)methyl]-4,5-dibromothiophene-2 10 carboxamide, and its hydrochloride; (-)-N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yl)(phenyl)methyl]-4,5-dibromothiophene-2 carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2.1.1 Ihex-1 -yl)(4-fluorophenyl)methyl]-3-chloro-4 (trifluoromethyl)pyridine-2-carboxamide; 15 N-[(2-Azabicyclo[2.1.1 ]hex-1 -yl)(phenyl)methyl]-2-(methylsulfanyl)nicotinamide; N-[(2-Azabicyclo[2.1.1 ]hex-1 -yl)(phenyl)methyl]-3-chloro-4-(trifluoromethyl)pyridine-2 carboxamide; N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yl)(phenyl)methyl]-1 -benzyl-1 H-indole-4-carboxamide; N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yl)(naphth-2-yl)methyl]-3-chloro-4 20 (trifluoromethyl)pyridine-2-carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2. 1.1] hex-1 -yi)(naphth-2-yl)methyl]-2-(methylsulfanyl)nicotinamide, and its hydrochloride; N-[(2-Azabicyclo[2. 1.1]hex-1 -yl)(3-methoxyphenyl)methyl]-3-chloro-4 (trifluoromethyl)pyridine-2-carboxamide, and its hydrochloride; 25 N-[(2-Azabicyclo[2.1.1]hex-1 -yl)(3-methoxyphenyl)methyl]-2 (methylsulfanyl)nicotinamide, and its hydrochloride; N-[(2-Azabicyclo[2.1.1 ]hex-1 -yl)(m-tolyl)methyl]-2-(methylsulfanyl)nicotinamide, and its hydrochloride; N-[(2-Azabicyclo [2.1.1 ]hex-1 -yl)(3-(trifl uoromethyl)phenyl)methyl]-3-ch loro-4 30 (trifluoromethyl)pyridine-2-carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2. 1.1] hex-1 -yl)(m-tolyl)methyl]-3-chloro-4-(trifluoromethyl)pyridine-2 carboxamide, and its hydrochloride; (+)-N-[(2-Allyl-2-azabicyclo[2. 1 .1 ]hex-1-yl)(phenyl)methyl]-4,5-dibromothiophene-2 carboxamide; 35 (-)-N-[(2-Allyl-2-azabicyclo[2. 1.1 ]hex-1 -yl)(phenyl)methyl]-4,5-dibromothiophene-2- WO 2010/106269 6 PCT/FR2010/050447 carboxamide; N-[(2-Benzyl-2-azabicyclo[2. 1.1 ]hex-1 -yl)(3-(trifluoromethyl)phenyl)methyl]-3-chloro-4 (trifluoromethyl)pyridine-2-carboxamide, and its hydrochloride; N-[(2-Benzyl-2-azabicyclo[2. 1.1]hex-1 -yl)(phenyl)methyl]-2,5-dichlorothiophene-3 5 carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2. 1.1] hex-1-y)(phenyl)methyl]-3,6-dichloropyridine-2-carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2. 1.1]hex-1 -yl)(phenyl)methyl]-3-chloro-5-(trifluoromethyl)pyridine-2 carboxamide; 10 N-[(2-Azabicyclo[2.1.1 ]hex-1 -yl)(phenyl)methyl]-6-chloro-3-(trifluoromethyl)pyridine-2 carboxamide. The compounds of the invention exhibit a specific activity as inhibitors of glycine transporters GlyT1, in particular an improved activity profile and an improved safety 15 profile. The compounds of general formula (1) can be prepared by a process illustrated by the following Scheme 1: 20 SCHEME 1 RV R NH 2 , (Il A diamine of general formula (II), in which R and R 1 are as defined above, in particular 25 when R represents a hydrogen atom or an allyl group, is coupled with an activated acid, for example an acid activated via a mixed anhydride or an acid chloride, of general formula (Ill), in which Y represents a leaving group derived, for example, from benzotriazole or acylurea or a halogen atom and R 2 is as defined above, using methods known to a person skilled in the art. 30 The compounds of general formula (1) in which R represents the hydrogen atom can also be prepared from compounds of general formula (1) in which R represents: WO 2010/106269 7 PCT/FR2010/050447 - either protective group which can be deprotected by hydrogenolysis, - or an allyl group, by deprotecting the nitrogen, for example with a palladium(0) complex, according to methods known to a person skilled in the art. 5 The compounds of general formula (1) in which R is other than the hydrogen atom can also be prepared from compounds of general formula (1) in which R represents a hydrogen atom either by alkylation of the said compound of general formula (1) with a halide or mesylate of the RX type, in which R is as defined above and X is mesylate or halogen, in the presence of an inorganic base, for example potassium carbonate in 10 acetonitrile; or by a reaction of Eschweiler-Clarke type or a reductive amination with an appropriate aldehyde or an appropriate ketone, according to methods known to a person skilled in the art; or with an appropriate epoxide derivative, according to methods known to a person skilled in the art. The compounds of general formula (1) in which the R, group is a phenyl group 15 substituted by a hydroxyl can be obtained from the corresponding compound of general formula (1) substituted by a methoxy, using methods known to a person skilled in the art. The diamine of general formula (II) can be prepared by processes illustrated by the following Scheme 2, for the amine (Ila), and the following Scheme 3, for the amines 20 (Ib) and (1Ic): WO 2010/106269 8 PCT/FR2010/050447 SCHEME2 0 CH 0 0 N N ("0N - (VI) (IV) (V) 0 W \-Ph R jRLi N (VilI) N N
CH
2 (X) CH 2 CH 2 (IX) (VII) Ri
NH
2
CH
2 (Ila) 5 The ester (IV) is converted to the amide (V) by heating the trimethylaluminium complex and the appropriate amine, such as morpholine, at reflux of the solvent, such as toluene. The amine (V) can be deprotected by using a lithium compound of phenyllithium type in a solvent, such as tetrahydrofuran, at low temperature, for example at -70"C. An N-alylation is subsequently carried out using allyl bromide in 10 the presence of a base, such as potassium carbonate, in a solvent, such as acetonitrile, at ambient temperature, in order to obtain the compound (VII). The morpholine amide of formula (VII) can be reacted with the lithiated aromatic compound of general formula (Vill), in which R is as defined above, in an ethereal solvent, such as ether or tetrahydrofuran, at low temperature. A ketone of general WO 2010/106269 9 PCT/FR2010/050447 formula (IX) is thus obtained and is reacted with O-benzylhydroxylamine hydrochloride, at reflux of pyridine, in order to obtain a Z/E mixture of oxime of general formula (X). The oxime (X) is subsequently reduced at reflux of the ether by lithium aluminium 5 hydride, in order to provide the diamine of formula (Ila). SCHEME 3 RR CR N
NH
2 NH2 N (Vill) H XA (IIc) (Xl) (llb) 10 According to Scheme 3, a nitrile of formula (XI) is reacted with the lithiated aromatic compound of general formula (VIII), in which R 1 is as defined above, in an ethereal solvent, such as tetrahydrofuran or ether, at low temperature, for example -70*C. An imine is thus obtained and is reduced with a reducing agent, such as sodium borohydride, in a protic solvent, such as methanol, to give the amine of general 15 formula (Ilb). The amine (11b) can be debenzylated by hydrogenation in the presence of palladium catalyst to provide the deprotected amine (Ic). Furthermore, the chiral compounds of general formula (1) corresponding to the S or R enantiomers can be obtained by separation of the racemic compounds by high 20 performance liquid chromatography (HPLC) on a chiral column or might be obtained by resolution of the racemic amine of general formula (II) by use of a chiral acid, such as dibenzoyltartaric acid, or by the fractional and preferential recrystallization of a diastereoisomeric salt. The ester of formula (IV) is prepared according to a method described in J. Org. 25 Chem., 2003, 9348-9355. The nitrile of formula (XI) is prepared according to a method described in Tetrahedron: Asymmetry, 2006 (17), 252-25. The lithiated derivatives of general formula (VIll) can be prepared according to methods known to a person skilled in the art.
WO 2010/106269 10 PCT/FR2010/050447 The acids and acid chlorides of general formula (111) are available commercially or are prepared by analogy to methods known to a person skilled in the art. The examples which will follow illustrate the preparation of some compounds of the 5 invention. In these examples: - the elemental microanalyses, the IR and NMR spectra and chiral column HPLC confirm the structures and the enantiomeric purities of the compounds obtained, - for the NMR descriptions, "m" means multiplet, "s" singlet, "t" triplet, "d" doublet, "q" quartet, "dxd" double doublet, "txt" triple triplet, "dxt" double triplet, and the like, 10 - the numbers shown between brackets in the titles of the examples correspond to those in the lt column in Table 1, - "decomp." means "decomposition", - for the compounds in the salt form, the figures between brackets indicate the (base:acid) ratio, 15 - "ee" means enantiomeric excess, - the nomenclature employed is the nomenclature according to the IUPAC (International Union of Pure and Applied Chemistry) recommendations. In the names of the compounds, the hyphen "-" forms part of the word and the 20 "underline" symbol "_" is used only for the break at the line end; it is to be omitted in the absence of a break and should be replaced neither by an ordinary hyphen nor by a space. Example I (compound No. 1): N-[(2-Al lyl-2-azabicyclo[2. 1.1] hex- 1 25 yl)(phenyl)methyl]-4,5-dibromothiophene-2-carboxamide 1.1 (2-Benzovl-2-azabicvclo[2. 1.1 1hex-1-y )(morpholin-4-vl)methanone 10 ml of morpholine (115 mmol) are added dropwise to a solution of 29 ml of 2N trimethylaluminium (58 mmol) in 200 ml of anhydrous toluene in a 500 ml three 30 necked flask under argon and the mixture is heated at 60 0 C for 15 minutes. A solution of 20 g of ethyl 2 -benzoyl-2-azabicyclo[2.1.1]hexane-1-carboxylate (77.1 mmol) in 190 ml of anhydrous toluene is transferred via a tube into the reaction medium, which is subsequently heated at reflux overnight. After cooling, the mixture is carefully hydrolysed with 60 ml of water while stirring. The precipitate formed is filtered off on 35 Celite@ and then rinsed with dichloromethane. The filtrate is evaporated under WO 2010/106269 11 PCT/FR2010/050447 reduced pressure. The residue obtained is triturated from ether. 18.35 g of (2-benzoyl-2 azabicyclo [2.1.1 ]hex-1 -yl)(morpholin-4-yl)methanone are thus obtained in the form of a dark beige solid. 5 'H NMR (400 MHz, de-DMSO) 8 ppm 7.69 (d, J = 8 Hz, 2H), 7.56-7.45 (m, 3H), 3.76 (d, J = 7.7 Hz, 1H), 3.64-3.26 (m, 9H), 2.73 (t, J = 2.7 Hz, 1H), 2.10 (m, 2H), 1.97 (m, IH), 1.52 (m, 1H). M.p.: 176-177*C 10 1.2. (2-Azabicyclo[2.1.llhex-1-vl)(morpholin-4-yl)methanone 10 g of (2-benzoyl-2-aza bicyclo[2.1.1 ]hex- 1 -yl)(morpholin-4-yl)methanone (compound obtained according to stage 1.1) (33.3 mmol) are placed in 400 ml of anhydrous tetrahydrofuran at -70*C in a 1 I three-necked flask under argon. 50 ml of 0.8M phenyllithium (cyclohexane/ether) (40 mmol) are added dropwise and the solution 15 obtained is left stirring at -70*C for 1 h. Hydrolysis is carried out with 100 ml of water and the mixture is allowed to return to ambient temperature. After extracting, the organic phase is concentrated and then the residue is taken up in ether. This ethereal phase is poured into the preacidified aqueous phase. After extracting, the aqueous phase is basified with aqueous 20 ammonia and then extracted with dichloromethane (3 x 200 ml). The organic phases are dried over sodium sulphate, filtered and evaporated under reduced pressure. 5.2 g of (2-azabicyclo[2.1.1]hex-1-yl)(morpholin-4-yl)methanone are thus obtained in the form of a dark beige solid. 1 H NMR (400 MHz, dr-DMSO) S ppm 3.71 (m, 2H), 3.55 (m, 4H), 3.44 (m, 2H), 2.87 25 (s, 2H), 2.69 (broad s, 1H), 2.60 (t, J = 2.9 Hz, 1H), 1.84 (m, 2H), 1.43 (m, 2H). M.p.: 97.5-98*C 1.3. (2-Allyl-2-azabicyclo[2. 1.1 lhex-1 -yll)(morholin-4-vl)methanone 7.4 g of (2-azabicyclo[2.1.1]hex-1-yI)(morpholin-4-yl)methanone (compound obtained 30 according to stage 1.2) (37.7 mmol) are placed in 100 ml of acetonitrile and 10.4 g of potassium carbonate (75.4 mmol) in a 500 ml round-bottomed flask. A solution of 3.9 ml of allyl bromide (45.2 mmol) is added dropwise to this suspension. The reaction medium is stirred overnight at ambient temperature and then concentrated under reduced pressure. 35 The residue is dissolved in 100 ml of dichloromethane. The organic phase is washed WO 2010/106269 12 PCT/FR2010/050447 with water, dried over sodium sulphate, filtered and then evaporated under reduced pressure. 8.9 g of (2-aIlyl-2-aza bicyclo [2.1.1] hex-1 -yl)(morpholin-4-yl)metha none are thus obtained in the form of an oil. 5 'H NMR (400 MHz, dr-DMSO) S ppm 5.85 (m, 1 H), 5.24 (m, 1 H), 5.09 (m, 1 H), 3.78 (broad t, J = 4.7 Hz, 2H), 3.54 (m, 4H), 3.44 (m, 2H), 3.05 (broad d, J = 5.7 Hz, 2H), 2.69 (broad s, 2H), 2.56 (broad t, J = 3 Hz, 1 H), 1.83 (m, 2H), 1.68 (m, 2H). 1.4. (2-Allyl-2-azabicyclo 2.1.1 hex-- I)(p henyl)methanone 10 3.2 g of (2-allyl-2-azabicyclo[2. 1.1 ]hex-1 -yl)(morpholin-4-yl)methanone (compound obtained according to stage 1.3) (13.5 mmol) are placed in 70 ml of tetrahydrofuran at -70"C in a 250 ml three-necked flask under argon. 16.2 ml of IM phenyllithium (cyclohexane/ether) are run in dropwise and the mixture is left at -70*C for one hour. After hydrolysis with 20 ml of water, the mixture is allowed to return to ambient 15 temperature. After evaporating the solvent under reduced pressure, the residue is taken up in ethyl acetate. After extracting, the organic phase is dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue is purified by chromatography on a column of silica gel, elution being carried out with a mixture of petroleum ether and ethyl acetate. 2 g of (2-allyl-2-azabicyclo[2.1.1]hex-1 20 yl)(phenyl)methanone are thus obtained in the form of an oil. 'H NMR (400 MHz, dr-DMSO) S ppm 8.28 (m, 2H), 7.64 (txt, J = 7.3 and 1.4 Hz, 1H), 7.52 (m, 2H), 5.73 (m, 1H), 5.20 (m, J = 17 and 2 Hz, 1H), 5 (m, J = 10 and 2 Hz, IH), 2.99 (dxt, J = 5.6 and 1.5 Hz, 2H), 2.86 (s, 2H), 2.70 (t, J = 2.9 Hz, 1H), 1.99-1.85 (m, 25 4H). 1.5. (2-Allyl-2-azabicyclo[2. 1. 1]hex-1 -yl)(phenyl)methanone O-benzyloxime 0.8 g of (2-allyl-2-azabicyclo[2. 1.1 ]hex-1 -yl)(phenyl)methanone (compound according to stage 1.4) (3.7 mmol) is placed in 12 ml of pyridine in a 50 ml round-bottomed flask 30 and then 0.91 g of O-benzylhydroxylamine hydrochloride (7.4 mmol) is added. The reaction medium is heated at reflux overnight and then concentrated under reduced pressure. The residue is taken up in water basified with aqueous ammonia and then extracted three times with dichloromethane. The organic phases are combined, washed with a 35 saturated sodium chloride solution, dried over sodium sulphate, filtered and WO 2010/106269 13 PCT/FR2010/050447 evaporated under reduced pressure. The crude product is purified by chromatography on a column of silica gel, elution being carried out with a mixture of dichloromethane and ammoniacal methanol. 1.2 g of (2-allyI-2-azabicyclo[2.1.1]hex-1 yl)(phenyl)methanone O-benzyloxime are thus obtained in the form of an oil. 5 'H NMR (400 MHz, dr-DMSO) S ppm 7.49-7.45 (m, 2H), 7.42-7.26 (m, 8H), 5.76 (m, 1H), 5.17 (m, J = 17 Hz and 1.7 Hz, IH), 5.09 (s, 1H), 5.03 (m, 1H), 3.06 (dxt, J = 5.9 Hz and 1.4 Hz, 2H), 2.66 (broad s, 2H), 2.62 (broad t, J = 3 Hz, 2H), 1.79 (m, 2H), 1.63 (m, 2H). 10 1.6. [(2-Allyl-2-azabicyclo[2.1.1lhex-1-yI)(phenyl)methyllamine 0.32 g of lithium aluminium hydride (8.4 mmol) is placed in 15 ml of ether in a 50 ml three-necked flask under nitrogen. A solution of 0.7 g of (2-allyl-2 azabicyclo[2.1.1]hex-1-yl)(phenyl)methanone O-benzyloxime (compound according to 15 stage 1.5) (2.1 mmol) in 3 ml of ether is subsequently added and then the mixture is heated at 40"C for 3 hours. After cooling, the reaction medium is hydrolysed at 0*C with 1.4 ml of a 0.1 M aqueous potassium sodium tartrate solution overnight. After filtering the reaction mediurh, the filtrate is concentrated under reduced pressure. The residue is purified by chromatography on a column of silica gel, elution being 20 carried out with a mixture of dichloromethane and ammoniacal methanol. 0.3 g of [(2-allyl-2-azabicyclo[2.1.1]hex-1-yl)(phenyl)methyl]amine is thus obtained in the form of an oil. 1 H NMR (400 MHz, d 6 -DMSO) S ppm 7.36-7.15 (m, 5H), 5.87 (m, 1H), 5.23 (m, 1H), 25 5.06 (m, 1H), 4.14 (s, 1H), 3.36 (m, J = 13.5 and 5.5 Hz, 1H), 3.06 (m, J = 13.5 and 6.4 Hz, 1H), 2.76 (broad d, J = 8 Hz, 1H), 2.43 (m, 2H), 1.78 (broad s, 2H), 1.39-1.21 (m, 3H), 1.08 (m, 1H). 1.7. N-[(2-Allyl-2-azabicyclo[2.1.1 hex-i-yI)(phenyl)methyl1-4,5-dibromothrophene-2 30 carboxamide 1.75 g of [(2-allyl-2-azabicyclo[2. 1.1 ]hex- 1 -yl)(phenyl)methyl]ami ne (compound according to stage 1.6) (7.66 mmol) are placed in 30 ml of dichloromethane at 00C in the presence of 2.1 g of potassium carbonate (15.3 mmol) in a 250 ml rodnd bottomed flask. A solution of 2.8 g of 4,5-dibromothiophene-2-carbonyl chloride 35 (9.2 mmol) in 20 ml of dichloromethane is added and the mixture is left stirring at WO 2010/106269 14 PCT/FR2010/050447 ambient temperature overnight. The reaction medium is subsequently diluted with 100 ml of dichloromethane and then washed successively with water (50 ml), a 1N sodium hydroxide solution (50 ml) and a saturated sodium chloride solution (50 ml). The organic phase is dried over sodium sulfate, filtered and evaporated under 5 reduced pressure. The residue is purified by chromatography on a column of silica gel, elution being carried out with a mixture of dichloromethane and ammoniacal methanol. 3.2 g of N-[(2-allyl-2-aza bicyclo[2.1.1 ]hex- I -yI)(phenyl)methyl]-4,5 dibromothiophene-2-carboxamide are thus obtained. 10 'H NMR (400 MHz, CDCL 3 ) 8 ppm 7.40-7.08 (m, 7H), 5.79 (m, 1H), 5.18 (m, 1H), 5.06 (m, 1 H), 4.98 (m, 1 H), 3.36 (m, 1 H), 3.07 (m, 1 H), 2.87 (m, 1 H), 2.54 (m, 1 H), 2.46 (m, 1H), 1.55-1.22 (m, 4H). M.p. = 59-60 0 C 15 Example 2 (compound No. 2): N-[(2-Azabicyclo[2.1.1]hex-1-yl)(phenyl)methyl] 4,5-dibromothiophene-2-carboxamide 4.7 mg of palladiumtetrakis(triphenylphosphine) (0.004 mmol) and 0.19 g of NN dimethylbarbituric acid (1.2 mmol) in solution in 2 ml of dichloromethane are placed in a 10 ml round-bottomed flask under argon provided with a reflux condenser. The 20 reaction medium is heated to 400C, then 0.2 g of N-[(2-allyl-2-azabicyclo{2.1.1]hex-1 yl)(phenyl)methyl]-4,5-dibromothiophene-2-carboxamide (compound 1) (0.4 mmol) in 2 ml of dichloromethane is added and then the mixture is heated at 40*C for a further 2 hours. After cooling, the mixture is diluted with 10 ml of dichloromethane and subsequently hydrolyzed with 5 ml of a sodium carbonate solution. 25 The organic phase is separated and washed twice with 5 ml of 1N hydrochloric acid. The aqueous phases are combined, then basified with aqueous ammonia to pH 9 and subsequently extracted twice with 25 ml of dichloromethane. The organic phases are dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue is purified by chromatography on a column of silica gel, elution being carried 30 out with a mixture of dichloromethane and ammoniacal methanol. 70 mg of N-[(2 azabicyclo[2.1.1] hex-1 -yl)(phenyl)methy]-4,5-dibromothiophene-2-carboxamide are thus obtained in the form of a powder. 1 H NMR (400 MHz, dr-DMSO) 6 ppm 8.69 (d, J = 8.8 Hz, 1H), 8.15 (s, 1H), 7.39 (m, 35 2H), 7.33 (m, 2H), 7.26 (m, 1 H), 5.29 (d, J = 7.8 Hz, 1 H), 2.79 (s, 2H), 2.63 (m, J = 2.8 WO 2010/106269 15 PCT/FR2010/050447 Hz, 1H), 1.62 (m, 2H), 1.15 (m, 2H). M.p. = 189-190*C Example 3 (compound No. 17): (+)-N-[(2-AllyI-2-azabicyclo[2.1.1]hex-1 5 yI)(phenyl)methyl]-4.5-dibromothiophene-2-carboxamide This compound is obtained by separation by preparative HPLC of N-[(2-Allyl-2 azabicyclo[2. 1.1 ]hex- 1-y)(phenyl)methyl]-4.5-dibromothiophene-2-carboxamide (compound No. 1) using a CHIRALpak@ AD 20 jm, and, as solvent, an 80/20 10 acetonitrile/propan-2-ol mixture. 'H NMR (400 MHz, de-DMSO) S ppm 8.65 (m, 1H), 8.15 (s, 1H), 7.4-7.2 (m, 5H), 5.75 (m, 1H), 5.40 (m, 1H), 5.30 (m, 1H), 5.02 (m, 1H), 3.20 (m, 2H), 2.70 (m, 1H), 2.60 2.50 (m, 2H), 1.58 (m, 1H), 1.4 (m, 3H). ee = 99.7% 15 [oe] 2 -c MeOH = +39.2* c = 0.475 g/100 ml Example 4 (compound No. 4): (+)-N-[(2-azabicyclo[2.1.1]hex-1 yI)(phenyl)methyl]-4,5-dibromothiophene-2-carboxamide, hydrochloride (1:1) 20 This compound is obtained according to the method described in Example 2 starting from compound No. 17 described according to Example 3, after salification in the hydrochloride form by dissolution of the base in ether, addition of an excess of 1 N hydrochloric acid in ether and then concentration under reduced pressure. 1 H NMR (400 MHz, dr-DMSO) S ppm 9.77 (m, 1H), 9.55 (d, J = 8.9 Hz, 1H), 8.93 (m, 25 1H), 8.46 (s, 1H), 7.56-7.38 (m, 5H), 5.70 (d, J = 9.2 Hz, 11H), 3.30 (m, 2H), 2.84 (m, 1H), 2.10 (m, 1H), 1.87 (m, 1H), 1.66 (m, 2H). M.p. = 211-213*C ee = 99.7% [ao]200c MeOH = +35.5" c = 1.02 g/1 00 ml 30 Example 5 (compound No. 18): (-)-N-[(2-Allyl-2-azabicyclo[2.1.1]hex-1 yl)(phenyl)methyl}-4,5-dibromothiophene-2-carboxamide The compound is obtained by separation by preparative HPLC of N-[(2-allyl-2 35 azabicyclo[2. 1.1 ]hex- I -yl)(phenyl)methyl]-4,5-dibromothiophene-2-carboxam ide WO 2010/106269 16 PCT/FR2010/050447 (compound No. 1) using a CHIRALpak@ AD 20 pm column and, as solvent, an 80/20 acetonitrile/propan-2-ol mixture. 1 H NMR (400 MHz, dr-DMSO) 8 ppm 8.65 (m, 1H), 8.15 (s, 1H), 7.4-7.2 (m, 5H), 5.75 (m, 1H), 5.40 (m, 1H), 5.30 (m, 1H), 5.02 (m, 1H), 3.20 (m, 2H), 2.70 (m, 1H), 2.60 5 2.50 (m, 2H), 1.58 (m, 1H), 1.4 (m, 3H). ee = 100% [ca] 2 o-c MeOH = -36.4" c = 0.45 g/100 ml Example 6 2 (compound No. 5): (-)-N-[(2-Azabicyclo[2.1.1]hex-1 10 yl)(phenyl)methyl]-4,5-dibromothiophene-2-carboxamide, hydrochloride (1:1) This compound is obtained according to the method described in Example 2 starting from compound No. 18 described according to Example 5, after salification in the hydrochloride form by dissolution of the base in ether, addition of an excess of 1N 15 hydrochloric acid in ether and then concentrated under reduced pressure. 'H NMR (400 MHz, dr-DMSO) S ppm 9.52 (d, J = 9.2 Hz, 1H), 8.42 (s, 1H), 7.50-7.34 (m, 5H), 5.66 (d, J = 8.9 Hz, 1H), 3.25 (m, 2H), 2.80 (m, 1H), 2.07 (m, 1H), 1.83 (m, 1 H), 1.62 (m, 2H). M.p. = 227-228*C 20 ee=100% [ao]20-c MeOH = -36.2* c = 1.02 g/1 00 ml Example 7 (compound No. 7)1: N-[(2-azabicyclo[2.1.1]hex-1-yl)(phenyl)methyl-2 (methylsulphanyl)nicotinamide 25 7.1 [(2-Benzyl-2-azabicyclo[2.1.-11Ihex-1 -yl)(phenyl)methyila mine 3 g of 2-benzyl-2-aza bicyclo[2.1.1 ]hexane-1 -carbon itrile (XI) (15.1 mmol) are placed at -70*C in 100 ml of anhydrous tetrahydrofuran in a 500 ml three-necked flask under argon. 37.8 ml of a 0.8M solution (cyclohexane/ether) of phenyllithium (30.2 mmol) 30 are added dropwise. The reaction mixture is left stirring at -70"C for two and a half hours and is then hydrolysed at -20*C with 30 ml of water. After extracting, the organic phase is concentrated and then the residue is taken up in 40 ml of methanol. 2.8 g of sodium borohydride (75 mmol) are added thereto 35 portionwise. The reaction medium is left stirring at ambient temperature overnight.
WO 2010/106269 17 PCT/FR2010/050447 After evaporating under reduced pressure, the residue is taken up in 100 ml of ether and 100 ml of water. The medium is acidified with a 1N hydrochloric acid solution and then the ethereal phase is extracted. 5 The aqueous phase is basified with aqueous ammonia and then reextracted twice with 100 ml of dichloromethane. The organic phases are combined and then dried over sodium sulphate, filtered and evaporated under reduced pressure. 4.15 g of [(2 benzyl-2-azabicyclo[2. 1.1 ]hex- 1 -yl)(phenyl)methyl]amine (11b) are thus obtained in the form of an oil which crystallizes in the cold. 10 'H NMR (200 MHz, CDCl 3 ) S ppm 7.6-7.3 (m, 5H), 4.4 (s, 1H), 4.2 (d, J = 16 Hz, 1H), 3.6 (d, J = 16 Hz, 1H), 3.0 (d, J = 9 Hz, 1H), 2.6 (m,1H), 2.4 (d, J = 9 Hz, 1H), 1.8 (broad s, 2H), 1.6-1.2 (m, 4H). M.p. = 63.5-64"C. 15 An analytical sample is obtained in the form of the hydrochloride by dissolution of the base in ether, addition of an excess of IN hydrochloric acid in ether and then concentration under reduced pressure. M.p. = 140-142 0 C 20 7.2 [(2-Azabicyclo2.1.1 ]hex-1-yI(phenyl)methylIamine 0.43 g of [(2-benzyl-2-azabicyclo[2. 1.1 ]hex-1 -yl)(phenyl)methyl]amine (1.54 mmol) is placed in 20 ml of ethanol and 5 ml of 1N hydrochloric acid, in the presence of a spatula tip of 10% palladium-on-charcoal, in a Parr bottle under 4 atmospheres of hydrogen at 40*C for 3 hours. 25 After filtering of the catalyst and concentrating the filtrate under reduced pressure, the residue is taken up in 30 ml of dichloromethane and 30 ml of water basified with aqueous ammonia. After extracting, the organic phase is dried over sodium sulphate, filtered and evaporated under reduced pressure. 0.24 g of [(2-azabicyclo[2. 1.1 ]hex-1 yl)(phenyi)methyl]amine is thus obtained in the form of a yellow oil which solidifies in 30 the cold and which is used as is in the following stage. M.p. = 46.5-47*C An analytical sample is obtained in the form of the hydrochloride by dissolution of the base in ether, addition of an excess of 1N hydrochloric acid in ether and then 35 concentration under reduced pressure.
WO 2010/106269 18 PCT/FR2010/050447 'H NMR (400 MHz, dr-DMSO) 8 ppm 10.12-8.71 (m, 4H), 7.46-7.35 (m, 6H), 4.83 (m, 1H), 3.15 (m, 2H), 2.72 (m, 1H), 2.10 (m, 1H), 1.89 (m, 1H), 1.57 (broad t, J = 9.3 Hz, 1H), 1.36 (broad t, J = 9.3 Hz, 1H). M.p. = 220-223*C (decomp.) 5 7.3 N- [2-aza bicyclo [2. 1.11 hex- 1 -y I he nvl meth i -2-( meth Isul I hanvI nicotin am ide 0.22 g of 2-(methylsulfanyl)nicotinic acid (1.27 mmol), 0.17 g of hydroxybenzotriazole (1.27 mmol) and 0.25 g of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (1.27 mmol) are placed in solution in 2 ml of dichloromethane in a 25 ml 10 round-bottomed flask and the mixture is stirred at ambient temperature for 15 minutes. 0.2 g (1.0 mmol) of [(2-azabicyclo[2.1.1]hex-1-yl)(phenyl)methyllamine in solution in 2 ml of dichloromethane is added and the mixture is stirred at ambient temperature overnight. The reaction medium is subsequently diluted with 10 ml of dichloromethane and then 15 successively washed with water (5 ml), with 1 N sodium hydroxide solution (5 ml) and with a saturated sodium chloride solution (5 ml). The organic phase is dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue is purified by chromatography on a column of silica gel, elution being carried out with a mixture of dichloromethane and ammoniacal 20 methanol. 63 mg of N-[(2-azabicyclo [2.1 .1] hex-1 -yl)(phenyl)methyl}-2 (methylsulphanyl)nicotinamide are thus obtained in the form of a powder. M.p. = 141-143*C 'H NMR (400 MHz, dr-DMSO) 6 ppm 8.79 (d, J = 8.5 Hz, 1H), 8.55 (dxd, J = 5 Hz and 1.7 Hz, 1H), 7.76 (dxd, J = 7.5 Hz and 1.8 Hz, 1H), 7.43-7.18 (m, 6H), 5.30 (d, J = 8.6 25 Hz, 1H), 2.77 (m, 2H), 2.63 (m, IH), 2.45 (s, 3H), 1.70 (m, 1 H), 1.64 (m, 1H), 1.14 (m, 2H). The other compounds described in Table 1 are obtained according to the methods described in Examples 1 to 7 starting from the appropriate amines of formula (Ila), 30 (Ib) or (llc), from appropriate lithium compounds of formula (VIII) or from appropriate carboxylic acid derivatives of formula (111). The chemical structures of some compounds of the invention are illustrated in the following Table 1. 35 In the column: - "Salts": "-" denotes a compound in the form of the base, "HCI" denotes a hydrochloride and the figure in brackets indicates the (base:acid) ratio, WO 2010/106269 19 PCT/FR2010/050447 - the compounds in the table are provided in the form of the hydrochloride solvated by one or more water molecules, In the R, R 1 and R 2 columns: - "Cl" means chlorine, 5 - "Br, means bromine, - "CH 3 " means methyl, - "OCH 3 " means methoxy, - "Ph" means phenyl, - "CF 3 " means trifluoromethyl, 10 - "Bn" means benzyl; - in the "R 2 " column, the figure in front of the substituents indicates the position in the general formula (1). The physical properties, melting points and optical rotations of the compounds of 15 Table 1 are given in Table 2. In Table 2: - the [ao]20-c column gives the analytical result for the optical rotation of the compounds in the table at the wavelength of 589 nM and at the temperature of 20C. The solvent shown in brackets corresponds to the solvent employed in carrying out 20 the measurement of the optical rotation in degrees and the letter "c shows the concentration of the solvent in g/100 ml. "N.A." means that the measurement of the optical rotation is not applicable, - the "m/z" column gives the molecular ion (M+H*) or (M*) observed by analysis of the products by mass spectrometry, either by LC-MS (Liquid Chromatography coupled to 25 Mass Spectroscopy), carried out on a device of Agilent LC-MSD Trap type in positive ESI mode, or by direct introduction by MS (Mass Spectroscopy) on an Autospec M (EBE) device using the DCI-NH 3 technique or using the electron impact technique on a device of Waters GCT type.
WO 2010/106269 20 PCT/FR2010/050447 TABLE 1 4 S 3 RO R H Hot
R
2 No. R R1 R 2 Salts Stereochemistry 4,5-Br2-thiophen 1 allyl Ph -yh h- racemic 2-yi 2 H Ph 4,5-Br 2 -thiophen- - racemic _____2-yI 3 H Ph 2,5-C1 2 -thiophen- racemic 3-yI 4 H Ph 4,5-Br 2 -thiophen- HCI chiral 2-yl (1:1) dextrorotatory 5 H Ph 4,5-Br2-thiophen- HCI chiral 2-y (1:1) laevorotatory 6 H 4-F-Ph 3-014-OF 3 - - racemic pyridin-2-yI 7 H Ph 2-SCH 3 -pyridin-3- - racemic yl 8 H Ph 3--4-F 3 -- racemic pyridin-2-yl - racemic 9 H Ph 1 -benzyl-indol-4-yl - racemic 3-CI-4-CF 3 - HCI 10 H .naphth-2-yl racemic pyridin-2-yI (1:1) 2-SCH 3 -pyridin-3- HCI 11 H naphth-2-yI racemic yI (1:1) 3-CI-4-CF3- HCI 12 H 3-OCH 3 -Ph 3-Cl-A--OF 3 - HOI racemic ____ pyridin-2-yl (1:1) 13 H 3-00H 3 -Ph 2-SCH 3 -pyridin-3- HCI racemic y1 (1:1) WO 2010/106269 21 PCT/FR2010/050447 2-SCH 3 -pyridin-3- HCI 14 H 3-CH3-Ph (1:1)raceic 15 H 3-CF 3 -Ph 3CI4CFr HCI race ic pyridin-2-yl (1:1) 16 H 3-CH 3 -Ph 3-CI-4-CF 3 -.. HCI racemic pyridin-2-yl (1:1) 17 allyl Ph 4,5-Brrthiophen- chiral 2-yl dextrorotatory 18 allyl Ph 4,5-Br 3 -thiophen- chiral 2-yl laevorotatory 19 Bn Ph 2-Ci-3-CF 3 - HCl racemic pyridin-2-y (1:1) HCI 20 Bn Ph 2,5-(CI) 2 -thien-3-yl racemic (1:1) 21 H Ph 3,6-(Cl)-pyridin-2- HCI racemic yl (1:1) 22 H Ph 3-CI-5-CF 3 - HCI racemic pyridin-2-yl (1:1) 23 H Ph 6-CI-3-CF3- HCI racemic pyridin-2-yl (1:1) WO 2010/106269 22 PCT/FR2010/050447 TABLE 2 No. M.p. ("C) [aDo-c* LCMS MH* 1 59-60 N.A. 495 2 189-190 N.A. 455 3 135-136 N.A. 367 4 211-213 +35.5 (MeOH) c=1.02 g/100 ml 455 5 227-228 -36.2 (MeOH) c=1.02 g/100 ml 455 6 183.5-184.5 N.A. 414 7 141-143 N.A. 340 8 153-154 N.A. 396 9 140-143 N.A. 422 10 199-200 N.A. 446 11 162-163 N.A. 390 12 119.5-120.5 N.A. 426 13 146-147 N.A. 370 14 195-196 N.A. 354 15 110-120 N.A. 464 16 150.5-151.5 N.A. 410 17 N.A. +39.2 (MeOH) c=0.475 g/100 ml 495 18 N.A. -36.4 (MeOH) c=0.457 g/100 ml 495 19 144-145 N.A. 486 20 165-166 N.A. 457 21 169.5-170.5 N.A. 362 22 133-134 N.A. 396 23 >300 N.A. 396 The compounds of the invention have been subjected to a series of pharmacological 5 trials which have demonstrated their advantage as substances possessing therapeutic activities. Study of glycine transportation in SK-N-MC cells expressing the native human 10 transporter GlyT1. The uptake of [ 14 C]glycine is studied in SK-N-MC cells (human neuroepithelial cells) expressing the native human transporter GlyTI by measuring the radioactivity incorporated in the presence or absence of the test compound. The cells are cultured as a monolayer for 48 hours in plates pretreated with 0.02% fibronectin. On the day of 15 the experiment, the culture medium is removed and the cells are washed with Krebs-HEPES (4-(2-hydroxyethyl)piperazine-1-etha nesul phonic acid) buffer at pH 7.4. After preincubation for 10 minutes at 37"C in the presence either of buffer (control batch) or of test compound at various concentrations or of 10 mM of glycine WO 2010/106269 23 PCT/FR2010/050447 (determination of the non-specific uptake), 10 pM of [ 4 C]glycine (specific activity 112 mCi/mmol) are subsequently added. Incubation is continued for 10 min at 37*C and the reaction is halted by washing twice with pH 7.4 Krebs-HEPES buffer. The radioactivity incorporated by the cells is then estimated after adding 100 pl of liquid 5 scintillant and stirring for 1 h. Counting is carried out on a Microbeta Tri-Luxlv counter. The effectiveness of the compound is determined by the IC5a, the concentration of the compound which reduces by 50% the specific uptake of glycine, defined by the difference in radioactivity incorporated by the control batch and the batch which received the 10 mM glycine. 10 The compounds of the invention have, in this test, an IC( of the order of 0.01 to 10 pM. Some examples of ICo results for compounds according to the invention are shown in Table 3. 15 TABLE 3 Compound ICa (pM) 3 0.46 8 0.11 9 0.35 12 0.097 15 0.22 20 0.055 The results of the in vitro trials carried out on the chiral compounds of the invention and their racemates according to the general formula (I) show that they are inhibitors 20 of the glycine transporter GlyT1 present in the brain. These results suggest that the compounds of the invention can be used for the treatment of cognitive and/or behavioural disorders associated with neurodegenerative diseases or dementia; for the treatment of psychoses, in particular schizophrenia (deficit form and productive form); or acute or chronic extrapyramidal 25 symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias or obsessive-compulsive disorders; for the treatment of various forms of depression, including pyschotic depression; for the treatment of bipolar disorders, manic disorders or mood disorders; or for the treatment of disorders due to alcohol WO 2010/106269 24 PCT/FR2010/050447 abuse or withdrawal, disorders of sexual behaviour, eating disorders, migraine, pain or sleep disorders. The compounds according to the invention can thus be used in the preparation of 5 medicaments, in particular of medicaments which are inhibitors of the glycine transporter GlyT1. Thus, according to another of its aspects, a subject-matter of the invention is medicaments which comprise a compound of formula (I) or an addition salt of the 10 latter with a pharmaceutically acceptable acid. Another subject-matter of the present invention is pharmaceutical compositions comprising an effective dose of at least one compound according to the invention, in the form of the base or a pharmaceutically acceptable salt, as a mixture, if appropriate, 15 with suitable excipients. The said excipients are chosen according to the pharmaceutical form and the method of administration desired. 20 The pharmaceutical compositions according to the invention may thus be intended for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal, rectal or intraocular administration. The unit administration forms can be, for example, tablets, gelatin capsules, granules, 25 powders, solutions or suspensions to be taken orally or to be injected, patches or suppositories. Ointments, lotions and collyria can be envisaged for topical administration. The said unit forms are dosed to allow a daily administration of 0.01 to 20 mg of active principle per kg of body weight, according to the pharmaceutical dosage form. 30 To prepare tablets, a pharmaceutical vehicle, which can be composed of diluents, such as, for example, lactose, microcrystalline cellulose or starch, and formulation adjuvants, such as binders (polyvinylpyrrolidone, hyd roxypropylmethylcellulose, and the like), flow agents, such as silica, or lubricants, such as magnesium stearate, 35 stearic acid, glyceryl tribehenate or sodium stearylfumarate, is added to the WO 2010/106269 25 PCT/FR2010/050447 micronized or unmicronized active principle. Wetting or surface-active agents, such as sodium lauryl sulphate, can also be added. The preparation techniques can be direct tableting, dry granulation, wet granulation or hot melt. 5 The tablets can be bare, coated with sugar, for example with sucrose, or coated with various polymers or other appropriate materials. They can be designed to make possible rapid, delayed or sustained release of the active principle by virtue of polymer matrices or of specific polymers used in the coating. 10 To prepare gelatin capsules, the active principle is mixed with dry pharmaceutical vehicles (simple mixing, dry or wet granulation, or hot melt) or liquid or semisolid pharmaceutical vehicles. The gelatin capsules can be hard or soft and coated or uncoated with a thin film, so as to have a rapid, sustained or delayed activity (for example, for an enteric form). 15 A composition in the form of a syrup or an elixir or for administration in the form of drops can comprise the active principle in conjunction with a sweetener, preferably a calorie-free sweetener, methylparaben or propylparaben, as antiseptic, a flavour enhancer and a colorant. 20 The water-dispersible powders and granules can comprise the active principle as a mixture with dispersing agents or wetting agents, or dispersing agents, such as polyvinylpyrrolidone, as well as with sweeteners and flavour-correcting agents. 25 Recourse is had, for rectal administration, to suppositories prepared with binders which melt at the rectal temperature, for example cocoa butter or polyethylene glycols. Use is made, for parental administration, of aqueous suspensions, isotonic saline solutions or injectable sterile solutions comprising pharmacologically compatible 30 dispersing agents and/or wetting agents, for example propylene glycol or butylene glycol. The active principle can also be formulated in the form of microcapsules, optionally with one or more vehicles or additives or else with a polymer matrix or with a 35 cyclodextrin (patches or sustained release forms).
WO 2010/106269 26 PCT/FR2010/050447 The topical compositions according to the invention comprise a medium compatible with the skin. They can be provided in particular in the form of aqueous, alcoholic or aqueous/alcoholic solutions, of gels, of water-in-oil or oil-in-water emulsions having 5 the appearance of a cream or of a gel, of microemulsions or of aerosols or in the form of vesicular dispersions comprising ionic and/or nonionic lipids. These pharmaceutical dosage forms are prepared according to methods conventional in the fields under consideration. 10 By way of example, a unit administration form of a compound according to the invention in the tablet form can comprise the following components: Compound according to the invention 50.0 mg Mannitol 223.75 mg 15 Croscarmellose sodium 6.0 mg Maize starch 15.0 mg Hyd roxypropylmethylcel I u lose 2.25 mg Magnesium stearate 3.0 mg 20 Orally, the dose of active principle administered daily can reach from 0.1 to 20 mg/kg, taken once or on several occasions. There may be specific cases where higher or lower dosages are appropriate; such dosages do not depart from the scope of the invention. According to the usual practice, the dosage appropriate to each patient is determined by the physician 25 according to the method of administration and the weight and the response of the said patient. The present invention, according to another of its aspects, also relates to a method for the treatment of the pathologies indicated above which comprises the administration, 30 to a patient, of an effective dose of a compound according to the invention or one of its pharmaceutically acceptable salts.

Claims (24)

1. Compound of general formula (1): R O N R HN 0 R Het R 2 in which: - R represents a hydrogen atom or a group chosen from (C 1 -C 6 )alkyl, (C 3 -C 7 )cyclo alkyl, benzyl or allyl groups which is optionally substituted by one or more groups chosen, independently of one another, from halogen atoms or (C 3 -C7)cycloalkyl, (C-Ce)alkyl, (C-C 6 )alkoxy or hydroxyl groups; - R 1 represents a phenyl or naphthyl group which is optionally substituted by one or more substituents chosen, independently of one another, from halogen atoms or (C 1 -C 6 )alkyl, (C-Ce)alkoxy, halo(C-C)alkyl, hydroxyl, halo(C-C 8 )alkoxy, (C C 6 )alkylthio, (C -C 6 )alkyl-SO or (C-C 6 )alkyl-SO 2 groups; - Het represents a heteroaryl group; - R 2 represents one or more substituents chosen from the hydrogen atom, halogen atoms or halo(C-C 6 )alkyl, (C-C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 3 -C 7 )cycloalkyl(C-C 3 )alkyl, (C-Ce)alkoxy, benzyl, (CI-C 6 )alkylthio, (C-C 6 )alkyl-SO or (C-C 6 )alkyl-S0 2 groups; in the form of the base or of an addition salt with an acid.
2. Compound of general formula (I) according to Claim 1, characterized in that R represents a hydrogen atom, a benzyl group or an allyl group; R 1 , Het and R 2 being as defined in claim 1, in the form of the base or of an addition salt with an acid.
3. Compound of general formula (1) according to Claim 1, characterized in that R 1 represents a phenyl or naphthyl group which is optionally substituted by one or more groups chosen, independently of one another, from halogen atoms or (C C 8 )alkyl, (C-C 6 )alcoxy or halo(C-Ce)alkyl groups; R, Het and R 2 being as defined in Claim 1, in the form of the base or of an addition salt with an acid. WO 2010/106269 28 PCT/FR2010/050447
4. Compound of general formula (1) according to Claim 1, characterized in that Het represents an indole, thiophene or pyridine group; R, R 1 and R 2 being as defined in Claim 1, in the form of the base or of an addition salt with an acid.
5. Compound of general formula (1) according to Claim 1, characterized in that R 2 represents one or more substituents chosen from the hydrogen atom, halogen atoms or halo(C1-C 6 )alkyl, benzyl or (C1-C 6 )alkylthio groups; R, R 1 and Het being as defined in Claim 1, in the form of the base or of an addition salt with an acid.
6. Compound of general formula (1) according to Claim 1, characterized in that - R represents a hydrogen atom, a benzyl group or an allyl group; - R, represents a phenyl or naphthyl group which is optionally substituted by one or more substituents chosen, independently of one another, from halogen atoms or (C 1 -Ce)alkyl, (C 1 -C 6 )alcoxy or halo(C 1 -C 6 )alkyl groups; - Het represents an indole, thiophene or pyridine group; - R 2 represents one or more substituents chosen from the hydrogen atom, halogen atoms or halo(C 1 -C)alkyl, benzyi or (C1-C 6 )alkylthio groups; in the form of the base or of an addition salt with an acid.
7. Compound of general formula (I) according to Claim I or 6, characterized in that - R represents a hydrogen atom, a benzyl group or an allyl group; - R 1 represents a phenyl or naphthyl group which is optionally substituted by one or more substituents chosen, independently of one another, from the fluorine atom or methyl, methoxy or trifluoromethyl groups; - Het represents an indole, thiophene or pyridine group; - R 2 represents one or more substituents chosen from the hydrogen atom, bromine or chlorine atoms or trifluoromethyl, methylthio or benzyl groups; in the form of the base or of an addition salt with an acid.
8. Compound according to one of Claims 1 to 7, characterized in that it is chosen from: N-{(2-Allyl-2-azabicyclo{2.1.1 ]hex- 1 -yl)(phenyl)methyl]-4,5-dibromothiophene-2 carboxamide; WO 2010/106269 29 PCT/FR2010/050447 N-[(2-Azabicyclo{2.1.1]hex-1 -yl)(phenyl)methyl]-4,5-dibromothiophene-2-carboxamide; N-[(2-Azabicyclo[2.1.1]hex-1 -yl)(phenyl)methyl]-2,5-dichlorothiophene-3-carboxamide; (+)-N-[(2-Azabicyclo[2.1.1 ]hex-1 -yl)(phenyl)methyl]-4,5-dibromothiophene-2 carboxamide, and its hydrochloride; (-)-N-[(2-Azabicyclo[2.1.1]hex-1 -yl)(phenyl)methyl}-4,5-dibromothiophene-2 carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yI)(4-fluorophenyl)methyl]-3-chloro-4 (trifluoromethyl)pyridine-2-carboxamide; N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yI)(phenyl)methyl]-2-(methylsulfanyl)nicotinamide; N-[(2-Azabicyclo[2. 1.1] hex-1 -yl)(phenyl)methyl]-3-chloro-4-(trifluoromethyl)pyridine-2 carboxamide; N-[(2-Azabicyclo[2. 1.1] hex-1 -yl)(phenyl)methyll-1 -benzyl-1 H-indole-4-carboxamide; N-(2-Azabicyclo[2. 1.1]hex-1 -yl)(naphth-2-yl)methyl]-3-chloro-4 (trifluoromethyl)pyridine-2-carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2.1.1]hex-1 -yl)(naphth-2-yl)methyl]-2-(methylsulfanyl)nicotinamide, and its hydrochloride; N-[(2-Azabicyclo[2.1.1 ]hex-1 -yl)(3-methoxyphenyl)methyl]-3-chloro-4 (trifluoromethyl)pyrid ine-2-ca rboxamide, and its hydrochloride; N-[(2-Azabicyclo[2. 1.1 ]hex-1 -yl)(3-methoxyphenyl)methyl}-2 (methylsulfanyl)nicotinamide, and its hydrochloride; N-[(2-Azabicyclo[2.1.1 ]hex-1 -yl)(m-tolyl)methyl]-2-(methylsulfanyl)nicoti namide, and its hydrochloride; N-[(2-Azabicyclo[2. 1.1]hex-1 -yI)(3-(trifluoromethyl)phenyl)methyl]-3-chloro-4 (trifluoromethyl)pyridine-2-carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2.1.1]hex-1 -yl)(m-tolyl)methyl]-3-chloro-4-(trifluoromethyl)pyridine-2 carboxamide, and its hydrochloride; (+)-N-[(2-Allyl-2-azabicyclo[2.1.1] hex-1 -yl)(phenyl)methyl]-4,5-dibromothiophene-2 carboxamide; (-)-N-[(2-Allyl-2-azabicyclo[2.1.1 ]hex-1 -yl)(phenyl)methyl]-4,5-dibromothiophene-2 carboxamide; N-[(2-Benzyl-2-azabicyclo[2.1.1 ]hex-1 -yl)(3-(trifluoromethyl)phenyl)methyl]-3-chloro-4 (trifluoromethyl)pyridine-2-carboxamide, and its hydrochloride; N-[(2-Benzyl-2-azabicyclo[2.1.1] hex-i -yl)(phenyl)methyl]-2,5-dichloroth iophene-3 carboxamide, and its hydrochloride; N-[(2-Azabicyclo[2.1.1 ]hex- 1 -yl)(phenyl)methyl]-3,6-dichloropyrid ine-2-carboxa m ide, WO 2010/106269 30 PCT/FR2010/050447 and its hydrochloride; N-[(2-Azabicyclo[2.1.1]hex-1 -yl)(phenyl)methyl]-3-chloro-5-(trifluoromethyl)pyridine-2 carboxamide; N-[(2-Azabicyclo[2.1.1]hex-1 -yl)(phenyl)methyll-6-chloro-3-(trifluoromethyl)pyridine-2 carboxamide.
9. Process for preparation of a compound of general formula (1) according to Claim 1, characterized in that a compound of general formula (II): RI R NH 2 in which R and R 1 are as defined according to Claim 1, reacts with a compound of general formula (111): Y O R2He in which Y represents a leaving group or a chlorine atom and Het and R 2 are defined according to Claim 1.
10. Compound of formula (11) Ri R NH 2 in which R and R 1 are defined according to Claim 1.
11. Medicament, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 8 or an addition salt of this compound with a pharmaceutically acceptable acid.
12. Pharmaceutical composition, characterized in that it comprises a compound of formula (1) according to any one of Claims 1 to 8 or a pharmaceutically acceptable salt of this compound and also at least one pharmaceutically acceptable excipient. WO 2010/106269 31 PCT/FR2010/050447
13. Use of a compound of formula (1) according to any one of Claims 1 to 8 in the preparation of a medicament intended for the treatment of cognitive and/or behavioural disorders associated with neurodegenerative diseases or dementia.
14. Use of a compound of formula (I) according to any one of Claims 1 to 8 in the preparation of a medicament intended for the treatment of psychoses, schizophrenia (deficit form and productive form) or acute or chronic extrapyramidal symptoms induced by neuroleptics.
15. Use of a compound of formula (I) according to any one of Claims 1 to 8 in the preparation of a medicament intended for the treatment of various forms of anxiety, panic attacks, phobias or obsessive-compulsive disorders.
16. Use of a compound of formula (I) according to any one of Claims 1 to 8 in the preparation of a medicament intended for the treatment of various forms of depression, including psychotic depression; in the treatment of bipolar disorders, manic disorders or mood disorders; or in the treatment of disorders due to alcohol abuse or withdrawal, disorders of sexual behaviour, eating disorders or migraine.
17. Use of a compound of formula (1) according to any one of Claims 1 to 8 in the preparation of a medicament intended for the treatment of pain.
18. Use of a compound of formula (1) according to any one of Claims 1 to 8 in the preparation of a medicament intended for the treatment of sleep disorders.
19. Compound according to any one of Claims 1 to 8, for the treatment of cognitive and/or behavioural disorders associated with neurodegenerative diseases or dementia.
20. Compound according to any one of Claims 1 to 8, for the treatment of psychoses, schizophrenia (deficit form and productive form) or acute or chronic extrapyramidal symptoms induced by neuroleptics.
21. Compound according to any one of Claims 1 to 8, for the treatment of various forms of anxiety, panic attacks, phobias or obsessive-compulsive disorders. WO 2010/106269 32 PCT/FR2010/050447
22. Compound according to any one of Claims 1 to 8, for the treatment of various forms of depression, including psychotic depression; for the treatment of bipolar disorders, manic disorders or mood disorders; or for the treatment of disorders due to alcohol abuse or withdrawal, disorders of sexual behaviour, eating disorders or migraine.
23. Compound according to any one of Claims 1 to 8, for the treatment of pain.
24. Compound according to any one of Claims 1 to 8, for the treatment of sleep disorders.
AU2010224720A 2009-03-16 2010-03-15 Derivatives of N-[(2-aza-bicyclo [2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics Abandoned AU2010224720A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0901219A FR2943056A1 (en) 2009-03-16 2009-03-16 New N-(2-aza-bicyclo(2.2.1)-hex-1-yl)-aryl-methyl-heterobenzamide derivatives are glycine transporter 1 inhibitors useful to treat e.g. dementia, psychosis, schizophrenia, anxiety, panic attacks, and obsessive compulsive disorder
FR09/01219 2009-03-16
FR0901810A FR2944283B1 (en) 2009-04-14 2009-04-14 N- (2-AZA-BICYCLO) -2.1.1-HEX-1-YL) -ARYL-METHYL-HETEROBENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR09/01810 2009-04-14
PCT/FR2010/050447 WO2010106269A2 (en) 2009-03-16 2010-03-15 Derivatives of n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics

Publications (1)

Publication Number Publication Date
AU2010224720A1 true AU2010224720A1 (en) 2011-10-06

Family

ID=42740053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010224720A Abandoned AU2010224720A1 (en) 2009-03-16 2010-03-15 Derivatives of N-[(2-aza-bicyclo [2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics

Country Status (14)

Country Link
EP (1) EP2408763A2 (en)
JP (1) JP2012520345A (en)
KR (1) KR20110132565A (en)
CN (1) CN102356074A (en)
AR (1) AR075837A1 (en)
AU (1) AU2010224720A1 (en)
CA (1) CA2755526A1 (en)
IL (1) IL215104A0 (en)
MX (1) MX2011009677A (en)
RU (1) RU2011141778A (en)
SG (1) SG174434A1 (en)
TW (1) TW201036980A (en)
UY (1) UY32495A (en)
WO (1) WO2010106269A2 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
FR2842805A1 (en) * 2002-07-29 2004-01-30 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND APPLICATION THERAPEUTICS
FR2842804B1 (en) * 2002-07-29 2004-09-03 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2861074B1 (en) * 2003-10-17 2006-04-07 Sanofi Synthelabo N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861071B1 (en) * 2003-10-17 2006-01-06 Sanofi Synthelabo N- [PHENYL (ALKYLPIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861070B1 (en) * 2003-10-17 2006-01-06 Sanofi Synthelabo DERIVATIVES OF N- [PHENYL (PYRROLIDIN-2-YL) METHYL] BENZAMIDE AND N - [(AZEPAN-2-YL) PHENYLMETHYL] BENZAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2861076B1 (en) * 2003-10-17 2006-01-06 Sanofi Synthelabo N-HETEROCYCLYMETHYLBENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
JP2009179562A (en) * 2006-08-11 2009-08-13 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor

Also Published As

Publication number Publication date
SG174434A1 (en) 2011-10-28
RU2011141778A (en) 2013-04-27
UY32495A (en) 2010-10-29
TW201036980A (en) 2010-10-16
JP2012520345A (en) 2012-09-06
CN102356074A (en) 2012-02-15
WO2010106269A3 (en) 2010-12-02
CA2755526A1 (en) 2010-09-23
AR075837A1 (en) 2011-04-27
WO2010106269A2 (en) 2010-09-23
MX2011009677A (en) 2011-09-30
KR20110132565A (en) 2011-12-08
EP2408763A2 (en) 2012-01-25
IL215104A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
US8513246B2 (en) Use of N-heterocyclylmethylbenzamides in therapeutics
EP3793997B1 (en) Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
BR112019015707A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION. USE OF A COMPOUND, COMBINATION OF A COMPOUND AND DEVICE
CN105814056B (en) Purine derivatives used as modulators of TNF activity
IE921987A1 (en) Azanorbornane derivatives
CN101903342B (en) Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and their therapeutic use as histamine H3 receptor modulators
KR20160040321A (en) Peptide deformylase inhibitors
AU2014400628A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
US20210309633A1 (en) Indazole carboxamides as kinase inhibitors
US20120029027A1 (en) N-[(6-aza-bicyclo[3.2.1]oct-5-yl)-aryl-methyl]-heterobenzamide derivatives, preparation thereof, and therapeutic use of same
CN112752757B (en) Tyrosine amide derivatives as RHO-kinase inhibitors
AU2010224720A1 (en) Derivatives of N-[(2-aza-bicyclo [2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics
US20120071536A1 (en) N-[(2-azabicyclo[2.1.1]hex-1-yl)-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof
EP4547247A2 (en) Deubiquitinase inhibitors and methods of use thereof
TW201329087A (en) Peptide deformylase inhibitors
HK40040371A (en) Tyrosine amide derivatives as rho- kinase inhibitors
FR2944283A1 (en) New N-((2-aza-bicyclo(2.1.1)hex-1-yl)-aryl-methyl)-heterobenzamide derivatives are glycine-1 transporters useful for treating e.g. cognitive disorders, psychotic depression, bipolar disorder, manic disorders and mood disorders
FR2943056A1 (en) New N-(2-aza-bicyclo(2.2.1)-hex-1-yl)-aryl-methyl-heterobenzamide derivatives are glycine transporter 1 inhibitors useful to treat e.g. dementia, psychosis, schizophrenia, anxiety, panic attacks, and obsessive compulsive disorder
HK1239693A1 (en) P2x7 modulators
HK1239693B (en) P2x7 modulators

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application